Logo

VERO

Venus Concept Inc.

VERO

Venus Concept Inc. • NASDAQ
$1.98 ▲ 3.13% (+0.06)
Market Cap $3.68 M
52w High $14.50
52w Low $1.65
Dividend Yield 0%
P/E -0.04
Volume 26.09K
Outstanding Shares 1.86M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $13.776M ▼ $18.313M ▼ $-22.565M ▼ -163.799% ▼ $-12.14 ▼ $-19.81M ▼
Q2-2025 $15.692M ▲ $18.472M ▲ $-11.721M ▲ -74.694% ▲ $-8.03 ▼ $-9.378M ▲
Q1-2025 $13.643M ▼ $18.283M ▲ $-12.363M ▼ -90.618% ▼ $-2.84 ▼ $-9.676M ▼
Q4-2024 $15.765M ▲ $17.56M ▲ $-7.965M ▲ -50.523% ▲ $-1.83 ▼ $-6.556M ▲
Q3-2024 $15.007M $17.078M $-9.286M -61.878% $-1.28 $-6.697M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $5.931M ▲ $61.624M ▼ $58.49M ▼ $2.673M ▲
Q2-2025 $3.878M ▲ $63.085M ▼ $60.313M ▼ $2.327M ▲
Q1-2025 $3.199M ▼ $63.46M ▼ $60.732M ▼ $2.262M ▼
Q4-2024 $4.271M ▼ $68.184M ▼ $65.346M ▲ $2.369M ▼
Q3-2024 $4.489M $72.276M $61.648M $10.108M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-22.565M ▼ $-4.89M ▲ $-17K ▲ $5.973M ▼ $1.066M ▼ $-4.907M ▲
Q2-2025 $-11.742M ▲ $-5.448M ▲ $-162K ▼ $7.276M ▲ $1.666M ▲ $-5.61M ▲
Q1-2025 $-12.366M ▼ $-6.31M ▼ $-35K ▲ $5.273M ▲ $-1.072M ▼ $-6.345M ▼
Q4-2024 $-8.016M ▲ $-3.807M ▼ $-80K ▼ $3.669M ▲ $-218K ▲ $-3.887M ▼
Q3-2024 $-9.302M $-3.049M $4K $1.802M $-1.243M $-3.045M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Leases
Leases
 $0 ▲$0 ▲$0 ▲$0 ▲
Product
Product
 $0 ▲$0 ▲$0 ▲$0 ▲
Service
Service
 $0 ▲$0 ▲$0 ▲$0 ▲
System
System
 $10.00M ▲$10.00M ▲$10.00M ▲$10.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Venus Concept is still very much in “turnaround” mode on the income side. Revenue is small and has not shown convincing growth over the last few years. The company does generate a positive margin on the products it sells, but that margin is not nearly enough to cover its operating costs. As a result, operating losses have been steady, and bottom‑line losses remain meaningful every year. Reported earnings per share look especially harsh because of multiple reverse stock splits, which magnify per‑share losses and highlight how challenged the business model has been so far.

Balance Sheet

Balance Sheet The balance sheet looks tight and fragile. The overall asset base is modest, with only a thin cash cushion. Debt is significant compared with the size of the company, while shareholders’ equity has hovered around break‑even and has even dipped negative at times. That combination points to financial strain and limited room for error. Management has been working to repair this through debt conversions and divesting the hair restoration business, but the company still appears financially stretched and heavily reliant on successful execution of its turnaround and new product launches.

Cash Flow

Cash Flow Cash flow has consistently been negative, mainly due to losses from day‑to‑day operations rather than heavy investment spending. The business is not currently funding its own growth from internally generated cash; instead it has depended on external capital and balance sheet maneuvers to stay afloat. Capital spending has been very light, which helps limit additional cash needs, but it also underscores how important it is for the core business to move closer to break‑even. Until operating cash flow turns sustainably positive, liquidity and funding will remain key risk areas to monitor.

Competitive Edge

Competitive Edge In its niche, Venus Concept has some genuine differentiators but also faces strong competition. Its devices target in‑demand aesthetic procedures like skin tightening and body contouring, where patient interest is rising, especially with more people experiencing loose skin after medical weight loss. The historic subscription model, bundled with marketing and practice support, helped the company stand out and build sticky customer relationships. However, the firm competes against larger and better‑capitalized players in medical aesthetics, and it is now shifting its model more toward cash sales while refocusing on core aesthetics after exiting hair restoration. That strategic reset raises both opportunity and execution risk: the positioning is sensible, but the company must prove it can win share and improve margins in a crowded market.

Innovation and R&D

Innovation and R&D Innovation is one of Venus Concept’s clearest strengths. It has built a portfolio of proprietary technologies in radiofrequency, pulsed electromagnetic fields, and advanced suction, all aimed at non‑invasive and minimally invasive treatments. The new Venus NOVA platform, with integrated muscle stimulation and IoT connectivity, represents a modern, data‑enabled device that aligns well with clinic needs for versatility and analytics. The planned next‑generation body contouring system further deepens its focus on post‑weight‑loss patients, a growing segment. Overall, the R&D story is forward‑leaning and well‑targeted, but the key question is not whether the technology is innovative—it is whether the company can commercialize these platforms at scale and at attractive economics.

Summary

Venus Concept sits at a critical crossroads. On one hand, it has cutting‑edge technology, a clear focus on high‑growth aesthetic niches like body contouring, and a business model that seeks to partner closely with clinics. On the other hand, it carries a history of persistent losses, a pressured balance sheet, ongoing cash burn, and significant dilution for shareholders, as reflected in repeated reverse stock splits. The sale of the hair restoration business and shift toward higher‑margin cash sales show that management is trying to simplify and strengthen the company. Going forward, the story will largely hinge on three things: the market uptake of Venus NOVA and future devices, the company’s ability to convert innovation into profitable, recurring revenue, and visible improvement in cash flow and financial stability. Until those pieces fall into place, Venus Concept remains a high‑risk, high‑execution‑sensitivity turnaround in a competitive but growing corner of medical aesthetics.

NEWS

November 13, 2025 · 7:00 AM UTC

Venus Concept Announces Third Quarter 2025 Financial Results

Read more

October 2, 2025 · 4:05 PM UTC

Venus Concept Announces $11.48 Million Debt-to-Equity Exchange Transaction

Read more

October 1, 2025 · 4:05 PM UTC

Venus Concept to Release Third Quarter of Fiscal Year 2025 Financial Results on November 13, 2025

Read more

September 19, 2025 · 8:30 AM UTC

Cellulite Treatment Market Size to Reach USD 5.19 Billion by 2032, Driven by Rising Demand for Non-Invasive Aesthetic Solutions | S&S Insider

Read more